Affiliation:
1. Hematology Division National Hospital Organization Disaster Medical Center Tokyo Japan
2. Nephrology Division National Hospital Organization Disaster Medical Center Tokyo Japan
3. Laboratory and Pathology Division National Hospital Organization Disaster Medical Center Tokyo Japan
4. Clinical Research Division National Hospital Organization Disaster Medical Center Tokyo Japan
Abstract
AbstractIntroductionHyperviscosity syndrome (HVS) is a significant complication in Waldenström's macroglobulinemia (WM), although the significance of plasmapheresis in clinical practice has not been clarified. To confirm the efficacy and safety of plasmapheresis followed by primary therapy for WM with HVS, we retrospectively conducted this study.MethodsUntreated WM with HVS, or serum immunoglobulin M (IgM) levels ≥4000 mg/dL, were analyzed. The basic therapeutic flow was conducted as follows: (1) performing plasmapheresis, (2) followed by primary therapy without rituximab, and (3) performing the second cycle. The serum IgM reduction rate and adverse events (AEs) were evaluated.ResultsTen patients were enrolled. The median serum IgM levels at diagnosis, post‐plasmapheresis, after the first cycle of primary therapy, and after the second cycle were 5174, 2900, 3286, and 2657 mg/dL, respectively. No patients experienced IgM flare or bleeding AEs.ConclusionThe therapeutic flow offers sufficient efficacy and safety in WM with HVS.
Reference23 articles.
1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
2. Evidence-based focused review of management of hyperviscosity syndrome
3. Acquired Von Willebrand disease in patients with Waldenström macroglobulinemia;Castillo JJ;Blood,2017
4. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenström macroglobulinemia
5. National Cancer Institute.NCCN clinical practice guidelines in oncology. Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. Version 2.2022. [cited 2022 February 6]. Available from:https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf